Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.55 |
| ▸ | LMNA | P02545 | 2/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | GRIA4 | P48058 | 2/20 | 0.49 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.49 |
| ▸ | EGFR | P00533 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | PADI4 | Q9UM07 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16144912 | 0.87 | LMNA (0.53) | KMT2ASMN1; SMN2LMNAKDM4ETDP1 | |
| SCHEMBL6017853 | 0.87 | SMN1; SMN2 (0.53) | KMT2ASMN1; SMN2LMNAKDM4ETDP1 | |
| SCHEMBL27749841 | 0.85 | PTGER1 (0.44) | KMT2ASMN1; SMN2LMNAKDM4EEGFR | |
| SCHEMBL7671576 | 0.83 | KMT2A (0.49) | KMT2ASMN1; SMN2LMNAKDM4ETDP1 | |
| SCHEMBL8687160 | 0.82 | ACLY (0.62) | KMT2AKDM4EGRIA4GRIA2EGFR | |
| SCHEMBL8784770 | 0.81 | TACR1 (0.55) | KMT2ASMN1; SMN2LMNAGRIA4GRIA2 | |
| SCHEMBL7134859 | 0.80 | KMT2A (0.44) | KMT2ASMN1; SMN2LMNAKDM4ETDP1 | |
| SCHEMBL4399199 | 0.80 | KMT2A (0.48) | KMT2ASMN1; SMN2LMNAKDM4ETDP1 | |
| SCHEMBL11791604 | 0.79 | KMT2A (0.62) | KMT2ASMN1; SMN2LMNAKDM4EL3MBTL1 | |
| SCHEMBL7607181 | 0.79 | KMT2A (0.43) | KMT2ASMN1; SMN2LMNAKDM4EMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11439622-B2 | Inhibitors of metallo-beta-lactamases | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2022-09-13 | — | — | US | claimed |
| CN-108602795-B | Inhibitors of metallo-beta-lactamases | 牛津大学科技创新有限公司 | 2022-04-22 | — | — | CN | claimed |
| US-20200375946-A1 | INHIBITORS OF METALLO-BETA-LACTAMASES | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2020-12-03 | — | — | US | claimed |
| CN-108602795-A | The inhibitor of metal-beta-lactamase | 牛津大学科技创新有限公司 | 2018-09-28 | — | — | CN | claimed |
| US-11439622-B2 | Inhibitors of metallo-beta-lactamases | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2022-09-13 | — | — | US | disclosed |
| CN-108602795-B | Inhibitors of metallo-beta-lactamases | 牛津大学科技创新有限公司 | 2022-04-22 | — | — | CN | disclosed |
| US-20200375946-A1 | INHIBITORS OF METALLO-BETA-LACTAMASES | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2020-12-03 | — | — | US | disclosed |
| US-20200375946-A1 | INHIBITORS OF METALLO-BETA-LACTAMASES | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2020-12-03 | — | — | US | disclosed |
| CN-108602795-A | The inhibitor of metal-beta-lactamase | 牛津大学科技创新有限公司 | 2018-09-28 | — | — | CN | disclosed |
| EP-2655323-B1 | INGENOL-3-ACYLATES III AND INGENOL-3-CARBAMATES | LEO LABORATORIES LTD (IE) | 2017-12-20 | — | — | EP | disclosed |
| US-20170217910-A1 | INGENOL-3-ACYLATES III AND INGENOL-3-CARBAMATES | LEO LABORATORIES LIMITED (IE) | 2017-08-03 | — | — | US | disclosed |
| US-9708286-B2 | Ingenol-3-acylates III and ingenol-3-carbamates | LEO LABORATORIES LIMITED (IE) | 2017-07-18 | — | — | US | disclosed |
| US-9102687-B2 | Ingenol-3-acylates III and ingenol-3-carbamates | LEO LABORATORIES LIMITED (IE) | 2015-08-11 | — | — | US | disclosed |
| CN-104529827-A | Ingenol-3-acylates III and ingenol-3-carbamates | LEO PHARMA AS | 2015-04-22 | — | — | CN | disclosed |
| US-20140303150-A1 | INGENOL-3-ACYLATES III AND INGENOL-3-CARBAMATES | LEO LABORATORIES LIMITED (IE) | 2014-10-09 | — | — | US | disclosed |
| CN-103402977-A | Ingenol-3-acylate III and Ingenol-3-carbamate | LEO PHARMA AS | 2013-11-20 | — | — | CN | disclosed |
| EP-2655323-A1 | INGENOL-3-ACYLATES III AND INGENOL-3-CARBAMATES | LEO LABORATORIES LIMITED (IE) | 2013-10-30 | — | — | EP | disclosed |
| WO-2012083953-A1 | INGENOL-3-ACYLATES III AND INGENOL-3-CARBAMATES | LEO PHARMA A/S (DK) | 2012-06-28 | — | — | WO | disclosed |
| WO-2002022576-A2 | 3-SUBSTITUTED INDOLE CARBOHYDRAZIDES USEFUL AS CELL PROLIFERATION AND ANGIOGENESIS INHIBITORS | ABBOTT LABORATORIES (US) | 2002-03-21 | — | — | WO | disclosed |
| US-3935193-A | ANTIBIOTICS | TOYO JOZO KABUSHIKI KAISHA (JA) | 1976-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170217910-A1 | INGENOL-3-ACYLATES III AND INGENOL-3-CARBAMATES | RXRB, RXRA, RXRG | KMT2A 3459/4885SMN1; SMN2 4677/4885LMNA 3996/4885 |
| US-20140303150-A1 | INGENOL-3-ACYLATES III AND INGENOL-3-CARBAMATES | RXRB, RXRA, RXRG | KMT2A 3459/4885SMN1; SMN2 4677/4885LMNA 3996/4885 |
| US-11439622-B2 | Inhibitors of metallo-beta-lactamases | IDO1, MGAM, LCT | KMT2A 1235/4885SMN1; SMN2 3913/4885LMNA 2052/4885 |
| US-20200375946-A1 | INHIBITORS OF METALLO-BETA-LACTAMASES | IDO1, MGAM, LCT | KMT2A 1235/4885SMN1; SMN2 3913/4885LMNA 2052/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.